Bayer is gradually evolving from a burdened legal and restructuring case into a recovery story. Crop Science is increasing profitability, while Nubeqa and Kerendia are seeing strong growth in the pharmaceutical business. Furthermore, the Apollo transaction strengthens the balance sheet. However, high financial debt, negative free cash flow, and the decline in sales for Xarelto and Eylea remain central risks.